Untitled

doi:10.18632/oncotarget.v8i22

Cited by 5 publications

(2 citation statements)

References 5 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regulating PTEN compartmentalization depends on a functional PML/HAUSP network, which is maximized in the stem cell compartment. Shuttling of PTEN is indeed associated with changes in cellular behaviours of various cancers 42,43. PTEN cellular compartmentation can be modulated by arsenic -trioxide, which affects the PML/HAUSP network, as we previously described.…”

Section: Cooperating Oncogenesmentioning

confidence: 55%

<p>Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells</p>

Carrà¹,

Cartellà²,

Maffeo³

et al. 2019

BLCTT

View full text Add to dashboard Cite

Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treatment represents the paradigm of molecular therapy of cancer. Since the development of the tyrosine kinase inhibitor of the BCR-ABL kinase, the clinical approach to CML has dramatically changed, with a stunning improvement in the quality of life and response rates of patients. However, it remains clear that tyrosine kinase inhibitors (TKIs) are unable to target the most immature cellular component of CML, the CML stem cell. This review summarizes new insights into the mechanisms of resistance to TKIs.

show abstract

Section: Cooperating Oncogenesmentioning

confidence: 55%

<p>Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells</p>

Carrà¹,

Cartellà²,

Maffeo³

et al. 2019

BLCTT

View full text Add to dashboard Cite

show abstract

“…Notably, the MAPK signaling pathway is also activated in GBC tissues from Chilean ( 51 ) and Indian ( 52 ) patients, underscoring the importance that it might have in driving gallbladder transformation. Remarkably, S6 represents an essential downstream effector of the ERK-MAPK signaling pathway ( 53 ). S6 is a ribosomal protein that regulates protein synthesis activated by the mTOR signaling pathway ( 54 , 55 ).…”

Section: Discussionmentioning

confidence: 99%

Early host immune responses in a human organoid-derived gallbladder monolayer to Salmonella Typhi strains from patients with acute and chronic infections: a comparative analysis

Salerno-Goncalves,

Chen,

Bafford

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Salmonella enterica serovar Typhi (S. Typhi), a human-restricted pathogen, invades the host through the gut to cause typhoid fever. Recent calculations of the typhoid fever burden estimated that more than 10 million new typhoid fever cases occur in low and middle-income countries, resulting in 65,400-187,700 deaths yearly. Interestingly, if not antibiotic-treated, upon the resolution of acute disease, 1%-5% of patients become asymptomatic chronic carriers. Chronically infected hosts are not only critical reservoirs of infection that transmit the disease to naive individuals but are also predisposed to developing gallbladder carcinoma. Nevertheless, the molecular mechanisms involved in the early interactions between gallbladder epithelial cells and S. Typhi remain largely unknown. Based on our previous studies showing that closely related S. Typhi strains elicit distinct innate immune responses, we hypothesized that host molecular pathways activated by S. Typhi strains derived from acutely and chronically infected patients would differ. To test this hypothesis, we used a novel human organoid-derived polarized gallbladder monolayer model, and S. Typhi strains derived from acutely and chronically infected patients. We found that S. Typhi strains derived from acutely and chronically infected patients differentially regulate host mitogen-activated protein kinase (MAPK) and S6 transcription factors. These variations might be attributed to differential cytokine signaling, predominantly via TNF-α and IL-6 production and appear to be influenced by the duration the isolate was subjected to selective pressures in the gallbladder. These findings represent a significant leap in understanding the complexities behind chronic S. Typhi infections in the gallbladder and may uncover potential intervention targets.

show abstract

Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer

Jarnagin,

Saraf,

Baiev

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

ImportancePatient-reported outcomes (PROs), such as quality of life (QOL) and symptoms, are often associated with clinical outcomes in patients with cancer. In practice, oncologists use serum tumor markers (TMs) (ie, carcinoembryonic antigen [CEA] and carbohydrate antigen 19-9 [CA 19-9]) and imaging to monitor clinical outcomes in patients with gastrointestinal cancer.ObjectiveTo examine associations of 1-month changes in PROs and TMs with treatment response and survival among patients with gastrointestinal cancer.Design, Setting, and ParticipantsThis cohort study enrolled patients at Massachusetts General Hospital Cancer Center with at least 1 month follow-up from May 2019 to December 2020. Included patients were beginning first-line systemic therapy, aged 18 years or older, and had been diagnosed with metastatic pancreaticobiliary, colorectal, or gastroesophageal cancer. Data analyses took place from January 2021 to January 2022.InterventionPROs were collected, including QOL (Functional Assessment of Cancer Therapy General [FACT-G]), physical symptoms (Edmonton Symptom Assessment System [ESAS]), and psychological symptoms (Patient Health Questionnaire-4 [PHQ4] total, PHQ4-depression, and PHQ4-anxiety), as well as TMs (CEA and CA 19-9), at the time of chemotherapy initiation and 1 month later.Main Outcomes and MeasuresAssociations of 1-month changes in PROs and TMs with treatment response (clinical benefit vs disease progression) at first scan, progression-free survival (PFS), and overall survival (OS), adjusted for baseline values using regression models.ResultsThis study included 159 patients, with 134 patients (84.3%) evaluable for analysis. Patients had a median (range) age of 64.0 (28.0-84.0) years and 86 (64.2%) were male. One-month PRO changes (FACT-G: OR, 1.07; 95% CI, 1.03-1.11; P = .001; ESAS-total: OR, 0.97; 95% CI, 0.94-1.00; P = .02; ESAS-physical: OR, 0.96; 95% CI, 0.92-1.00; P = .03; PHQ4-depression: OR, 0.67; 95% CI, 0.49-0.92; P = .01) were significantly associated with treatment response, but PHQ4-total or TMs were not. Changes in FACT-G (HR, 0.97; 95% CI, 0.95-0.99; P = .003), ESAS-total (HR, 1.03; 95% CI, 1.01-1.05; P = .004), ESAS-physical (HR, 1.03; 95% CI, 1.00-1.05; P = .02), PHQ4-depression (HR, 1.22; 95% CI, 1.01-1.48; P = .04), and CEA (HR, 1.00; 95% CI, 1.001-1.004; P = .001) were associated with PFS, but changes in PHQ4-total or TMs were not. Changes in ESAS-total (HR, 1.03, 95% CI, 1.01-1.06; P = .006) and ESAS-physical (HR, 1.04, 95% CI, 1.01-1.06; P = .015) were associated with OS, but changes in TMs were not associated with OS.Conclusions and RelevanceThese findings suggest that 1-month changes in PROs can be associated with treatment response and survival in patients with advanced gastrointestinal cancer. Notably, 1-month changes in TMs were not consistently associated with these outcomes. These findings highlight the potential for monitoring early changes in PROs to associate with clinical outcomes while underscoring the need to address the QOL and symptom concerns of patients with advanced cancer.

show abstract

Untitled

Abstract: News on: Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species by Wang et al. Oncotarget.

Cited by 5 publications

References 5 publications

<p>Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells</p>

<p>Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells</p>

Early host immune responses in a human organoid-derived gallbladder monolayer to Salmonella Typhi strains from patients with acute and chronic infections: a comparative analysis

Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer

Contact Info

Product

Resources

About